Cor Vasa 2005, 46(10):379-383

The presence and future of antiplatelet therapy with GP IIb/IIIa receptor antagonists

Petr Widimský
Kardiocentrum, Fakultní nemocnice Královské Vinohrady a 3. lékařská fakulta Univerzity Karlovy, Praha, Česká republika

This review article summarizes the currently available information about the use of GP IIb/IIIa receptor antagonists in clin-ical cardiology. Clinical trials with abciximab, tirofiban and eptifibatide are discussed. Their role in acute coronary syndromes and in interventional cardiology is analyzed.

Keywords: Abciximab; Tirofiban; Eptifibatide; PCI

Published: October 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Widimský P. The presence and future of antiplatelet therapy with GP IIb/IIIa receptor antagonists. Cor Vasa. 2005;46(10):379-383.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)

    • Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes